PeptideSearch

BPC-157

Almost all animal studies

Get notified when the evidence changes.

Almost all the research is in animals. There is at least one small study in people, but nobody was compared against an untreated group, so it cannot tell us much on its own.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-08-04

Also called Body Protection Compound 157 / PL 14736 / Bepecin

A lab-made peptide studied for wound and gut healing, almost entirely in rats and mice. Human research is very limited and it is not approved as a medicine anywhere.

The basics

What is it?
A lab-made chain of 15 amino acids, copied from part of a protein found in human stomach fluid. It is sold as a research chemical, not as a medicine.
What do we know?
Most of what we know comes from rats and mice. In those animals, cuts and tears in tendon, muscle, gut and blood vessel walls tend to close faster when BPC-157 is given. That pattern has been repeated in many separate animal experiments.
What do we still not know?
Almost everything about people. Our library holds one small study in people: 12 women with bladder pain, with no comparison group. A safety study in healthy volunteers has been registered, and a Phase 2 trial in hamstring injuries is recruiting, but neither has reported results. There is no agreed dose and no long-term safety record in humans. Much of the writing about BPC-157 is review articles going back over the same animal work, not new evidence.

Watch: what the research shows

BPC-157: What The FDA Panel Actually Voted On

An FDA advisory panel voted 8-6 to recommend BPC-157 for compounding, against the agency's own scientists. Here's what that changes, and what it doesn't. Our library holds 93 papers on BPC-157, 1 of them done in people.

Official status: Not nominated for 503A compounding · Checked 2026-08-04

Can a doctor prescribe this?

Small pharmacy (503A)
An FDA panel said yes — nothing has changed yet
Large outsourcing facility (503B)
Never put forward to FDA

Anything sold under this name is sold as a research chemical, not as a treatment.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

What FDA actually looked at

FDA reviewed this peptide for Ulcerative colitis. That is a narrower question than the uses this peptide is usually marketed for.

What happens next

FDA has not said whether it will move BPC-157 into Category 1 while it decides. It also has not started the formal rulemaking process.

Category 1 is the only thing that would let pharmacies make BPC-157 before rulemaking finishes. FDA has given no date. Rulemaking on its own takes more than a year, and FDA has finished this process for only about ten substances in nearly a decade.

The July 2026 vote covered the 503A list only. FDA has not scheduled any review of BPC-157 for the separate 503B list.

503B outsourcing facilities are the only way a peptide reaches large-scale telehealth supply. That list is a separate process with a different legal standard, and nothing has moved on it.

Lab suppliers we list: 17

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

Spot an error? corrections@peptidesearch.org

What has happened so far

  1. 23 July 2026503A

    In its briefing document, FDA proposed that BPC-157 NOT be included on the 503A Bulks List. FDA staff cited a lack of reliable data.

    FDA briefing documentnot yet verified against primary source

  2. 23 July 2026503A

    The 14-member advisory committee voted 8-6 with one abstention to recommend BPC-157 for the 503A Bulks List, going against FDA's own scientists. The vote is advisory only. It does not make BPC-157 an approved drug and does not on its own let any pharmacy compound it.

    8–6, 1 abstained

    Press reportnot yet verified against primary source

  3. 16 April 2026503A

    FDA published a Federal Register notice announcing a Pharmacy Compounding Advisory Committee meeting for July 23-24, 2026 at the White Oak campus, to consider seven peptides for the 503A Bulks List.

    Federal Registernot yet verified against primary source

We'll email you when a new study, trial or status change lands for BPC-157. Unsubscribe in one click.